

August 08, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Friday, August 08, 2025

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited (“the Company”) would like to inform you that the Board of Directors of the Company in its meeting held on Friday, August 08, 2025 at 02:00 P.M., have *inter alia*, discussed and approved the following business:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith **(Annexure-I)**.

Unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e at www.nseindia.com and on Company’s website at www.zotahealthcare.com.

The Board meeting concluded at 05:00 P.M.

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

PRADEEP K SINGHI & ASSOCIATES**CHARTERED ACCOUNTANTS**

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,

**The Board of Directors of
Zota Health Care Limited**

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter ended June 30, 2025** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (the "Regulations").

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pradeep K Singhi & Associates

Chartered Accountants

FRN : 0126027W

Date: 08-08-2025

Pradeep Kumar Singhi

Place: Surat

(Partner)


M. No. 200/024612


UDIN: 25024612BMONKG9563


Particulars		Quarter Ended			Year Ended
		30-06-2025 (Unaudited)	31-03-2025 (Audited)	30-06-2024 (Unaudited)	31-03-2025 (Audited)
I.	Revenue from Operations	7800.70	7793.25	5220.36	25727.61
II.	Other Income	223.39	149.53	46.88	462.34
III.	Total Income	8024.09	7942.78	5267.25	26189.94
IV.	Expenses:				
	Cost of Materials Consumed	490.52	609.03	279.11	1622.76
	Purchases of Stock-in-Trade	3442.21	5577.95	2344.68	15530.50
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-	536.90	(1445.69)	560.23	(1614.25)
	Employee Benefit Expenses	997.58	886.75	644.17	3114.97
	Finance Costs	3.68	7.93	41.92	105.59
	Depreciation / Amortisation and Depletion Expense	79.68	94.37	67.64	317.11
	Other Expenses	1618.96	1770.49	1097.29	5928.92
	Total Expenses	7169.54	7500.83	5035.03	25005.61
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	854.56	441.95	232.21	1184.33
VI.	Exceptional Items				
VII.	Profit/(loss) before tax	854.56	441.95	232.21	1184.33
VIII.	Tax Expense:				
	(1) Current tax	223.68	203.91	64.71	338.13
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	(0.00)	-	(2.49)
	(2) Deferred Tax	(40.44)	22.29	(9.07)	13.03
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	590.44	260.33	158.43	861.72
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII.	Profit/ (Loss) for the period	590.44	260.33	158.43	861.72
XIV.	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Statement of profit and loss	(16.09)	6.13	10.62	19.11
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	4.05	(1.54)	(2.67)	(4.81)
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-
	Other comprehensive income for the period, net of tax	(12.04)	4.58	7.94	14.30
	Total comprehensive income for the period (XIII + XIV)	578.40	264.91	166.37	876.01
	Paid-up Equity Share Capital	2976.66	2863.50	2653.43	2863.50
	Other Equity				28873.37
	Earnings per equity share of face value of ₹ 10 each				
	(1) Basic (in ₹)	2.03	0.92	0.60	3.16
	(2) Diluted (in ₹)	1.88	0.86	0.60	2.91


* denotes figures less than a lakh

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya
Date: 08-08-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
**The Board of Directors of
Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter ended June 30, 2025** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as amended from time to time (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- i. Zota Health Care Limited (Parent)
- ii. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
- iii. Davaindia Health Mart Limited (Wholly Owned Subsidiary)

- iv. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- v. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- vi. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited total revenues of Rs. 5248.79 Lakhs, total net profit/(loss) after tax of Rs. (1961.51) Lakhs and total comprehensive income of Rs. (1959.98) Lakhs, for the quarter ended June 30, 2025, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Pradeep K Singhi & Associates

Chartered Accountants

FRN : 0126027W

Date: 08-08-2025

Pradeep Kumar Singhi

Place: Surat

(Partner)


M. No. 200/024612


UDIN: 25024612BMONKH3634


healthcare ltd.		Quarter Ended		Year Ended	
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
Particulars					
I.	Revenue from Operations	10358.26	9727.46	5630.06	29297.48
II.	Other Income	87.61	100.15	1.79	206.80
III.	Total Income	10445.87	9827.61	5631.85	29504.28
IV.	Expenses:				
	Cost of Materials Consumed	490.52	609.03	279.11	1622.76
	Purchases of Stock-in-Trade	4185.61	6221.19	2321.63	16257.53
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(162.85)	(2042.73)	33.36	(4149.96)
	Employee Benefit Expenses	3317.31	2593.62	1624.65	8606.62
	Finance Costs	323.90	345.80	289.80	1078.34
	Depreciation / Amortisation and Depletion Expense	1467.84	1431.50	802.35	4319.61
	Other Expenses	2132.02	2099.69	1497.20	7533.82
	Total Expenses	11754.35	11258.09	6848.09	35268.71
V.	Profit before Exceptional Items and tax from continuing operations (III-IV)	(1308.48)	(1430.49)	(1216.24)	(5764.43)
VI.	Exceptional Items	-	-	-	-
VII.	Profit/(loss) before tax	(1308.48)	(1430.49)	(1216.24)	(5764.43)
VIII.	Tax Expense:				
	(1) Current tax	244.25	203.91	64.71	338.13
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	(0.00)	-	(2.49)
	(2) Deferred Tax	174.94	345.54	8.57	426.19
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1377.79)	(1288.86)	(1272.39)	(5673.89)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII.	Profit/ (Loss) for the period	(1377.79)	(1288.86)	(1272.39)	(5673.89)
XIV.	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Statement of profit and loss	(14.04)	15.89	12.39	40.31
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	3.53	(3.98)	(3.12)	(10.11)
	B (i) Items that will be reclassified to Statement of profit and loss	0.01	(0.01)	(0.06)	(0.05)
	(ii) Income Tax relating to items that will be reclassified to profit and loss	*	*	0.01	0.01
	Other comprehensive income for the period, net of tax	(10.51)	11.90	9.23	30.16
	Total comprehensive income for the period (XIII + XIV)	(1388.29)	(1276.96)	(1263.16)	(5643.73)
	Profit attributable to:				
	Owners of the parent	(1431.58)	(1289.04)	(1272.39)	(5639.84)
	Non-controlling interest	53.79	0.18	-	(34.05)
	Other comprehensive income attributable to:				
	Owners of the parent	(12.08)	11.90	9.23	30.16
	Non-controlling interest	1.57	-	-	-
	Total Comprehensive Income attributable to:				
	Owners of the parent	(1443.66)	(1277.14)	(1263.16)	(5609.68)
	Non-controlling interest	55.37	0.18	-	(34.05)
	Paid-up Equity Share Capital	2976.66	2863.50	2653.43	2863.50
	Other Equity	-	-	-	19504.98
	Earnings per equity share of face value of ₹ 10 each				
	(1) Basic (in ₹)	(4.92)	(4.57)	(4.80)	(20.68)
	(2) Diluted (in ₹)	(4.56)	(4.28)	(4.80)	(19.06)


* denotes figures less than a lakh

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya
Date: 08-08-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter ended June 30, 2025 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on August 08, 2025.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The figures for quarter ended March 31, 2025 are balancing figures between the audited figures of the financial year ended March 31, 2025 and the published figures of the year-to-date (nine months) ended December 31, 2024, which were subjected to limited review report.
4. The Statutory Auditors have carried out Limited Review of the financial results for the quarter ended June 30, 2025.
5. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
6. The consolidated results include the result of following companies:
 - A) Wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Private Limited
 - ii) Everyday Herbal Beauty and Wellness Care Private Limited
7. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 14323.60 lakhs and a corresponding Lease Liability of Rs.15371.31 lakhs as at June 30, 2025. The impact of this on the consolidated profit for the quarter ended June 30, 2025 is Rs. 187.40 lakhs.
8. During the quarter, the Company has issued and allotted 7,95,000 equity shares of Rs. 10/- each on a preferential basis at Rs. 900/- per equity share on April 17, 2025.
9. During the quarter; upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has on May 20, 2025 and June 10, 2025 allotted 33,484 and 3,03,065 equity shares upon conversion of warrants.
10. During the quarter, on April 01, 2025, the company has granted 67,500 stock options under Zota Health Care - Employee Stock Option Plan 2022' ("ZHL ESOP 2022"). As on June, 30, 2025, the Company has on cumulative basis granted 1,10,730 stock options under Zota Health Care - Employee Stock Option Plan 2022. Further, the options granted are yet to be exercised.

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122



11. During the quarter, on June 13, 2025 Company has made an investment of Rs. 4924.42 lakhs by subscribing 1,18,518 equity shares of M/s Davaindia Health Mart Limited at the price of Rs. 4155 (including premium of Rs. 4145) per shares.
12. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

